Adcc - OmicsDI

Show results for

Unknown (1203)
Genomics (79)
Transcriptomics (57)
Proteomics (13)
Clinical (7)
Other (5)
Models (1)
Genomic (1)
Metabolomics (1)

Organisms

Homo sapiens (71)
Alphavirus (10)
Archaea (10)
Bacteria (10)
Betaherpesvirinae (10)
Borrelia (10)
Botrytis cinerea (10)
Clostridium perfringens (10)
Eukaryota (10)
Fungi (10)
Hepatitis B virus (10)
Human betaherpesvirus 5 (10)
Influenza A virus (10)
Influenza C virus (10)
Insecta (10)
Japanese encephalitis virus group (10)
Mammarenavirus (10)
Miscanthus x giganteus (10)
Mycobacterium tuberculosis (10)
Orthoflavivirus (10)
Panicum virgatum (10)
Pseudomonas aeruginosa (10)
Rattus (10)
Saccharomyces cerevisiae (10)
Schizosaccharomyces (10)
Schizosaccharomyces pombe (10)
Severe acute respiratory syndrome coronavirus 2 (10)
Staphylococcus aureus (10)
Macaca mulatta (8)
Mus musculus (5)

Organisms

Homo sapiens (39)
Macaca mulatta (7)
Mus musculus (5)

Repository

ENA (58)
geo (47)
biostudies-arrayexpress (19)
EGA (17)
pride (10)
MassIVE (3)
BioModels (1)
dbGaP (1)
MetaboLights (1)

Tissue

Blood (3)
Cell culture (3)
Neutrophil (2)
B cell (1)
Fibroblast (1)
IgG short lived plasma cell (1)
Natural killer cell (1)
Peripheral blood mononuclear cell (1)
Stem cell (1)

Disease

Colorectal Neoplasms (4)
Carcinoma (2)
Disease free (2)
Neoplasm Metastasis (1)
Chronic lymphocytic leukemia (1)
Colon cancer (1)
Human cytomegalovirus infection (1)
Human immunodeficiency virus infectious disease (1)

Technology Type

Mass Spectrometry (10)
Bottom-up proteomics (5)
Data-independent acquisition (3)
Illumina HiSeq 2000, Illumina Genome Analyzer II (2)
Gel-based experiment (2)
Shotgun proteomics (2)
ILLUMINA, NextSeq 500 (1)
Illumina HiSeq 2000 (1)
Illumina HiSeq 2000, ILLUMINA (1)
Mass spectrometry (1)
Data-dependent acquisition (1)

Instrument Platform

MS:1001581 (1)
Orbitrap Eclipse (1)
Orbitrap Exploris 480 (1)
Q Exactive (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2023 (13)
2024 (11)
2025 (11)
2013 (7)
2026 (6)
2022 (6)
2021 (6)
2015 (3)
2014 (3)
2009 (3)
2011 (2)
2020 (2)
2019 (2)
2018 (2)
2012 (1)
2010 (1)
2008 (1)
2017 (1)

CHEBI ID

CHEBI:143106 (1)
CHEBI:81810 (1)
CHEBI:166563 (1)
CHEBI:139445 (1)
CHEBI:41094 (1)
CHEBI:167860 (1)
CHEBI:167740 (1)
CHEBI:183489 (1)
CHEBI:193016 (1)
CHEBI:183418 (1)
CHEBI:183375 (1)
CHEBI:177535 (1)
CHEBI:25682 (1)
CHEBI:52153 (1)
CHEBI:34187 (1)
CHEBI:7027 (1)
CHEBI:67040 (1)
CHEBI:15890 (1)
CHEBI:31445 (1)
CHEBI:15694 (1)
CHEBI:31747 (1)
CHEBI:17061 (1)
CHEBI:177850 (1)
CHEBI:143235 (1)
CHEBI:16523 (1)
CHEBI:165632 (1)
CHEBI:16269 (1)
CHEBI:66892 (1)
CHEBI:132583 (1)
CHEBI:41308 (1)

Metabolite Name

Uridine 5'-diphosphoglucuronic acid (1)
2,5-di-tert-Butylhydroquinone (1)
L-Glutathione (reduced) (1)
N-Acetyl-1-aspartylglutamic acid (1)
Uridine 5'-diphosphogalactose (1)
L-Glutathione oxidized (1)
Uridine monophosphate (UMP) (1)
Guanosine monophosphate (GMP) (1)
Cyclic ADP-ribose (1)
AICA ribonucleotide (1)
Thymidine 5'-monophosphate (1)
Folic acid (1)
S-Lactoylglutathione (1)
UDP-N-acetylglucosamine (1)
(+/-)12(13)-DiHOME (1)
D-Raffinose (1)
Adenosine 5'-monophosphate (1)
DL-Tryptophan (1)
Adenosine diphosphate (ADP) (1)
(+/-)9-HpODE (1)
Pantothenic acid (1)
Gluconic acid (1)
Citric acid (1)
(15Z)-9,12,13-Trihydroxy-15-octadecenoic acid (1)
Dibutyl phthalate (1)
Adenosine (1)
Uridine 5'-diphosphate (UDP) (1)
Tetradecanedioic acid (1)
Palmitic acid (1)
N-Acetyl-L-phenylalanine (1)

First Public Date

2023 (15)
2024 (12)
2025 (8)
2021 (5)
2026 (3)
2022 (3)
2017 (3)
2020 (2)
2019 (2)
2014 (2)
2018 (1)
2016 (1)
2013 (1)

Modelling Approach

Ordinary differential equation model (1)

Study status

Completed (3)
Recruiting (2)
Withdrawn (1)
Active, not recruiting (1)

Lab affiliation

Cambridge Institute for Medical Research, University of Cambridge, Hills Road, Cambridge, CB2 0XY, UK (1)
Center for Regeneration and Aging,BGI-haangzhou (1)
Dept. of Glycoconjugate Biochemistry Institute of Zoology and Biomedical Research Jagiellonian University (1)
Dept. of Molecular Hematology, Sanquin Research, Amsterdam, the Netherlands, and Landsteiner Laboratory, University of Amsterdam, Amsterdam, the Netherlands (1)
Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany (1)
Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute, Badalona, Spain (1)
Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain Medical Oncology Department, Reina Sofía University Hospital, Córdoba, Spain (1)
PI The Wistar Institute, Philadelphia, PA, USA; (1)
Sanquin Research, Amsterdam, NL (1)
University of Copenhagen, Institute for Cellular and Molecular Medicine (1)

Keyword

Cetuximab (4)
ADCC (2)
EGFR Positive (2)
EGFR+ (2)
EGFR (2)
Ionizing radiation (1)
Antibody-Dependant Cell Cytotoxicity (ADCC) (1)
Immuno-Radiation effect (1)
Stereotactic Body Radio-Therapy (SBRT) (1)
Natural killer cell therapy (1)
Antibody-dependent cell-mediated cytotoxicity (1)
Abscopal effect (1)
NPC-1C (1)
Ductal carcinoma of the pancreas (1)
Duct cell carcinomas, pancreas (1)
Carcinomas, pancreas duct cell (1)
Pancreas duct cell carcinoma (1)
Pancreatic duct cell carcinoma (1)
Targeted therapies (1)
AFM24 (1)
SNK01 (1)
NK cells (1)
IgG1 (1)
CD16A (1)
ADCP (1)
NK cell therapy (1)
Antibody (1)
Colorectal tumor (1)
Renal cancer (1)
Adenocarcinoma of the pancreas (1)

IsPrivate

False (1)

Submitter Keywords

Immuno-oncology (1)

Study type

Transcription profiling by array (15)
Interventional (7)
Comparative genomic hybridization by array (3)
ChIP-chip by tiling array (1)

Release Date

2022 (135)
2023 (117)
2024 (116)
2021 (116)
2025 (103)
2020 (100)
2019 (86)
2016 (80)
2018 (78)
2017 (70)
2015 (53)
2013 (41)
2014 (38)
2012 (22)
2026 (21)
2011 (17)
2009 (12)
2010 (10)
2008 (3)
2007 (1)
2003 (1)
2001 (1)
2000 (1)

Location

United States (3)
France (2)
Italy (1)
China (1)

Previous page
1 / 137
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 137
Next page

Sort by:

Relevance

Page size

Hoffman2018- ADCC against cancer

The paper describes a model of ADCC. Created by COPASI 4.26 (Build 213) This model is described in the article: A mathematical model of antibody-dependent cellular cytotoxicity (ADCC) F. Hoffman, D. Gavaghan, J. Osborne, I.P. Barrett, T. You, H. Ghadially, R. Sainson, R.W. Wilkinson, H.M. Byrne...

2024-09-02 | BIOMD0000000802 | BioModels

Immuno-oncology

Immunotherapy Utilizing NK cells and ADCC Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition

PRJNA498086 | ENA

Homo sapiens

Salivary Gland Exome Sequencing - AdCC and PLGA

PRJNA203011 | ENA

Immunotherapy Utilizing NK cells and ADCC Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition

Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining olaparib with immunotherapy in prostate cancer patients bo...

ORGANISM(S): Homo sapiens

2018-12-11 | GSE121682 | GEO

FcγR Binding and ADCC Activity of Human IgG Allotypes.

Not available

S-EPMC7218058 | biostudies-literature

SIV sequencing for Grunst et al, ADCC protection

PRJNA1031618 | ENA

FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV.

Not available

S-EPMC6916223 | biostudies-literature

CD4 mimetics sensitize HIV-1-infected cells to ADCC.

Not available